How to appeal a Blue Cross Blue Shield of Massachusetts pediatric oncology denial

The framework that applies to your appeal

Federal law gives you the right to a full and fair internal appeal, then an external review by an independent third party.

Blue Cross Blue Shield of Massachusetts-specific note: Non-profit; ~3M members. MA has the most expansive state mandated benefits in the US and strong supplemental parity rules. MA OPP (Office of Patient Protection) provides external review separately from carriers — distinct from federal IRO process for fully-insured plans.

What Blue Cross Blue Shield of Massachusetts's policy requires for pediatric oncology

Cited policy: BCBS Tumor-Agnostic Targeted Therapy (Vitrakvi / Rozlytrek / Koselugo / Ojemda)

Documented molecular biomarker (NTRK fusion / NF1 mutation / BRAF V600E / BRAF fusion). Age-appropriate per FDA label. Prescribed by/in consultation with pediatric oncologist.

How Blue Cross Blue Shield of Massachusetts denies pediatric oncology — and how to counter it

Where Blue Cross Blue Shield of Massachusetts pushes back: 1) Off-label use; 2) Not on formulary; 3) Try chemo first.

Counter-arguments that hold up: Vitrakvi (larotrectinib) tumor-agnostic FDA approval Nov 26, 2018 — by definition NOT off-label when NTRK fusion documented. Drilon NEJM 2018 + Laetsch Lancet Oncol 2018 pediatric SCOUT. Koselugo (selumetinib) FDA Apr 10, 2020 NF1 plexiform neurofibromas (SPRINT NEJM 2020). Ojemda (tovorafenib) FDA Apr 23, 2024 pediatric LGG. Submit NGS report + matched FDA label.

What Blue Cross Blue Shield of Massachusetts typically denies for pediatric oncology

Across Blue Cross Blue Shield of Massachusetts's commercial and Medicare books, denials cluster around a small number of patterns. For pediatric oncology, expect:

• MA-specific mandated benefit disputes (most generous in US)
• Behavioral health parity (MA has tighter parity rules than federal MHPAEA)
• Tiered-network provider disputes
• Specialty drug PA

Treatments most often denied in this category

These are the pediatric oncology treatments most often flagged for prior auth, step therapy, or medical necessity review:

• COG trial enrollment
• CAR-T (Kymriah)
• Proton therapy
• Pediatric immunotherapy
• Targeted therapy
• ALL chemo regimen

How to submit the appeal to Blue Cross Blue Shield of Massachusetts

1. Read the denial letter — note the exact denial reason code and the appeal deadline (180 days from the date on the letter).
2. Gather supporting documentation: physician letter of medical necessity, relevant clinical notes, peer-reviewed citations supporting the treatment for your indication, and the policy or coverage document Blue Cross Blue Shield of Massachusetts cited in the denial.
3. File the appeal through Blue Cross Blue Shield of Massachusetts's portal (members: https://home.bluecrossma.com ; providers: https://provider.bluecrossma.com). Standard decision returns within 30 days; expedited urgent appeals return within 72 hours.
4. If denied again, request external review by an independent reviewer within 4 months of the final internal denial. In MA, the state insurance department coordinates external review for fully-insured plans; ERISA self-funded plans use a federal external review through DOL/EBSA.

Clinician or prior-auth team handling this on the practice side? See Blue Cross Blue Shield of Massachusetts's prior-authorization criteria by drug: Blue Cross Blue Shield of Massachusetts PA criteria on ApprovalHelp.